Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AAK1 | Q2M2I8 | 11/20 | 0.52 |
| ▸ | SCN10A | Q9Y5Y9 | 8/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19388413 | 0.89 | AAK1 (0.57) | AAK1SCN10A | |
| SCHEMBL15116794 | 0.89 | AAK1 (0.57) | AAK1SCN10A | |
| SCHEMBL18483087 | 0.87 | AAK1 (0.52) | AAK1KDM4EMAPT | |
| SCHEMBL15125224 | 0.84 | AAK1 (0.54) | AAK1SCN10A | |
| SCHEMBL19388320 | 0.79 | AAK1 (0.48) | AAK1SCN10A | |
| SCHEMBL15116788 | 0.79 | AAK1 (0.48) | AAK1SCN10A | |
| SCHEMBL15116605 | 0.79 | AAK1 (0.48) | AAK1SCN10A | |
| SCHEMBL20054526 | 0.79 | AAK1 (0.48) | AAK1SCN10A | |
| SCHEMBL19388627 | 0.79 | AAK1 (0.48) | AAK1SCN10A | |
| SCHEMBL18483092 | 0.77 | AAK1 (0.50) | AAK1SCN10A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10617675-B2 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2020-04-14 | — | — | US | disclosed |
| US-20180221342-A1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2018-08-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10617675-B2 | Hepatitis C virus inhibitors | HAVCR2, MAVS, EIF2AK2 | AAK1 2213/4885SCN10A 4191/4885KDM4E 3572/4885 |
| US-20180221342-A1 | HEPATITIS C VIRUS INHIBITORS | HAVCR2, MAVS, EIF2AK2 | AAK1 2213/4885SCN10A 4191/4885KDM4E 3572/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.